tbuckley/cabot-search huggingface dataset:
Abstract 3447: Identification of Gastric Cancer-Specific Helicobacter Pylori Genes Using Suppression Subtractive Hybridization
Authors: Yue-hua Gong, Liu Jun, Yuan Yuan
Journal: Cancer Research (2010)

Abstract Helicobacter pylori (H. pylori), a microaerophilic Gram negative bacterium, is known to cause chronic gastritis, peptic ulcer, and gastric cancer. Genes that are present in certain isolates may determine strain-specific traits such as drug resistance. In order to understand the pathogenic mechanisms of gastric diseases, identify the molecule markers of the diseases associated with H.pylori strains, and provide clue for the target treatment of H. pylori related diseases, a subtracted DNA library was constructed from a gastric cancer-associated H. pylori strain and a superficial gastritis-associated H. pylori strain by suppression subtractive hybridization. Differentially expressed genes were identified by dot blot hybridization and DNA sequencing. Twelve high copy genes and 9 low-copy genes were found in gastric cancer-associated strain compare to superficial gastritis strain. These differentially expressed genes were confirmed by PCR analysis of bacteria isolates. Interestingly, PPIase was detected positively in 13 out of 26 H pylori strains derived from gastric cancer patients. In contrast, less than 24% of H pylori strains from superficial gastritis showed positive. Our results suggest that PPIase may represent a novel marker and potential therapeutic target for gastric cancer. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3447.
Brundtland replaces top staff at the WHO
Authors: A. Mach
Journal: BMJ (1998)

The World Health Organisation's top staff has been replaced by an entirely new team. The announcement came on 21 July--the day Dr Gro Harlem Brundtland, former prime minister of Norway, assumed office as the WHO's new director general.

Since January Dr Brundtland's transition team has been working to mastermind a radical break with the WHO's tarnished past in terms of a new leadership, structure, priorities, and operations. Despite nervous grumbling about the “heavy input” from headquarters and a lack of transparency in the “Scandinavian-Anglo-Saxon mafia” the transition team seems to have achieved its goal.

The names of the new appointees to the WHO's cabinet were unveiled in Dr Brundtland's first teleconference address to the WHO's 3500 staff around the world on the day of her arrival.

It is rumoured that the Norwegian government has placed a sizeable sum ($30m; £19m) at the WHO's disposal to ease the departure of staff whose services will no longer be required.

Unusual within the United …
Fully covered self-expanding metal stents for refractory pancreatic duct strictures in chronic pancreatitis
Authors: C. Giacino, P. Grandval, R. Laugier
Journal: Endoscopy (2012)

Fully covered self-expanding metal stents (FC-SEMSs), which can be removed from the bile duct, have recently been used in the main pancreatic duct (MPD) in chronic pancreatitis. The aim of this study was to investigate the feasibility, safety, and efficacy of FC-SEMSs in painful chronic pancreatitis with refractory pancreatic strictures. The primary endpoints were technical success and procedure-related morbidity. Secondary endpoints were pain relief at the end of follow-up and resolution of the dominant pancreatic stricture at endoscopic retrograde pancreatography. Over 5 months, 10 patients with painful chronic pancreatitis and refractory dominant pancreatic duct strictures were treated with FC-SEMSs. All FC-SEMSs were successfully released and removed, although two stents were embedded in the MPD at their distal end and treated endoscopically without complications. Mild abdominal pain was noted in three patients after stent release. During treatment, pain relief was achieved in nine patients, but one continued to take morphine, because of addiction. Cholestasis developed in two patients and was treated endoscopically; no patient developed acute pancreatitis or pancreatic sepsis. After stent removal, the diameter of the narrowest MPD stricture had increased significantly from 3.5 mm to 5.8 mm. Patients were followed up for a mean of 19.8 months: two patients who continued drinking alcohol presented with mild acute pancreatitis; one patient developed further chronic pancreatic pain; and one had a transient pain episode. At the end of the study, nine patients no longer had chronic pain and no patients had required surgery. Endoscopic treatment of refractory MPD stricture in chronic pancreatitis by placement of an FC-SEMS appears feasible, safe, and potentially effective.
P865 IS HEPATIC RESECTION INDICATED ONLY FOR SINGLE SMALL HEPATOCELLULAR CARCINOMA? VALIDATION OF THE EASL/AASLD GUIDELINES BASED ON OUR EXPERIENCE
Authors: S. Tanaka, Y. Iimuro, T. Hirano, S. Hai, I. Nakamura, Y. Kondo, K. Suzumura, T. Okada, S. Nishiguchi, J. Fujimoto
Journal: Journal of Hepatology (2014)
Cigarette Smoking and Leukemia
Authors: J. K. MCLAUGHLIN, Z. HRUBEC, M. S. LINET, E. F. HEINEMAN, W. J. BLOT, J. F. FRAUMENI
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Cigarette Smoking and Leukemia Get access JOSEPH K. MCLAUGHLIN, JOSEPH K. MCLAUGHLIN * Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer InstituteBethesda, MD 20892 *Dr. Joseph K. McLaughlin, Division of Cancer Etiology, National Cancer Institute, Executive Plaza North, Rm. 415, Bethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar ZDENEK HRUBEC, ZDENEK HRUBEC Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer InstituteBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar MARTHA S. LINET, MARTHA S. LINET Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer InstituteBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar ELLEN F. HEINEMAN, ELLEN F. HEINEMAN Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer InstituteBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar WILLIAM J. BLOT, WILLIAM J. BLOT Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer InstituteBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JOSEPH F. FRAUMENI, JR. JOSEPH F. FRAUMENI, JR. Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer InstituteBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 16, 16 August 1989, Pages 1262–1263, https://doi.org/10.1093/jnci/81.16.1262 Published: 16 August 1989
SPECT/CT Imaging of Patella Metastasis From a Squamous Carcinoma of the Lung
Authors: Bing Wu, Yan Xiu, Lei Jiang, Hongcheng Shi
Journal: Clinical Nuclear Medicine (2013)

A 71-year-old man presented with a progressive right knee pain which persisted for 6 months and was not relieved by pain medications. He had a history of lung squamous carcinoma 1 year ago. X-ray and magnetic resonance imaging (MRI) revealed hyperostosis, degenerative changes, and occupancy lesions of the right patella. The patient underwent 99mTc methylene diphosphonate (99mTc-MDP) bone scan and single photon emission tomography/computed tomography (SPECT/CT), which showed abnormal metabolism of the right patella with bone destruction and soft tissue swelling. Finally, patellectomy was taken and pathology confirmed patella metastasis from lung squamous carcinoma.
Events Leading to Major Amputation in Patients with Arteriosclerosis
Authors: Edward A. Edwards, A. James McAdams, Chilton Crane
Journal: New England Journal of Medicine (1953)

THE treatment of arteriosclerosis of the legs has changed considerably in the past several years, notably through the introduction of antibiotics and anticoagulants and through the recognition of the value of sympathectomy. These advances have been accompanied by a substantial reduction in the incidence of major amputation. A further reduction in the loss of extremities might follow a clearer recognition of the causes of gangrene or of causes not formerly appreciated. Added benefit should result from scrutiny of treatment of the arteriosclerotic patient, and especially of methods of handling a necrosis that is still localized.To obtain information bearing on . . .
PTH-193 Malignant Tumours of the Small Intestine: A 7 Year Study at a District General Hospital
Authors: S Mansukhani, A Arnaout, S Gupta
Journal: Gut (2013)

<h3>Introduction</h3> Malignant tumours involving the small intestine are among the rarest types of cancer. They present difficulties in early diagnosis and management. We analysed the records of all such patients at our hospital over the last 7 years to address the challenge in early recognition and diagnosis. <h3>Methods</h3> We retrospectively reviewed the case notes of all patients with operated small intestine tumours identified from histopathology records from 2004 to 2011. Clinical records, discharge summaries and imaging reports were reviewed for demographics, presenting symptoms, diagnostic workup, histopathology and outcome. <h3>Results</h3> 255 patients were identified of which 32 (13%) were malignant tumours. Mean age was 71 years (range 59 to 88). Male to female ratio was 3:5. There were 15 (47%) metastatic tumours involving the small intestine (14 adenocarcinomas). Of the 17 primary tumours, there were 4 (13%) adenocarcinomas, 5 (16%) carcinoid, 4 (13%) gastrointestinal stromal tumour (GIST), 3 (9%) lymphomas and 1 (2%) sarcoma. Of the patients with metastases, 9 presented with bowel obstruction, 4 with perforations and 2 with chronic abdominal pain. Of the 17 patients with primary tumours, the presenting symptoms were chronic abdominal pain (5 patients), systemic symptoms (5), bowel obstruction (3), small bowel perforation (2), gastro-intestinal bleeding (1) and 1 patient was diagnosed at surgery. In the metastases group, 6 were diagnosed on computerised tomography (CT) and 1 on magnetic resonance imaging (MRI). 2 of the 6 diagnosed on CT had recent normal abdominal ultrasound (US). The remaining 8 patients were diagnosed at the time of surgery. 7 of the 8 patients had recent cross sectional imaging which did not pick up the tumour. In the primary tumour group, 1 case was diagnosed on US and 7 on CT (2 of these patients had previous US which did not reveal the tumour). The remaining 9 patients were diagnosed at the time of surgery. 7 of these 9 patients had recent imaging (including CT, Barium meal, US and MRI) which did not pick up the tumour. In the metastases group, 9 were treated with palliative surgery, 4 had surgery with adjuvant chemotherapy and 2 had curative surgery. In the primary tumours group, 8 had curative surgery, 4 had surgery with adjuvant chemotherapy, 2 patients had neoadjuvant chemotherapy and surgery, 1 had surgery with adjuvant chemotherapy and radiotherapy and 2 were treated with palliative intent. 60% of those with metastases to the small bowel died within 2 years of diagnosis and 18% with primary tumours died within 2 years. <h3>Conclusion</h3> Most patients with metastatic disease present as emergencies while those with primary tumours present with more non-specific symptoms. We require a high index of suspicion and various imaging and endoscopic modalities (including wireless capsule endoscopy) for early diagnosis. <h3>Disclosure of Interest</h3> None Declared.
SAT0136 Focus on Implementation of Cardiovascular Risk Factor Recording for Patients with Rheumatoid Arthritis in A Rheumatology Outpatient Clinic
Authors: E. Ikdahl, S. Rollefstad, I.C.O.C. Olsen, T.K. Kvien, I.J.W. Hansen, D.M. Soldal, G. Haugeberg, A.G. Semb
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> There is a need for implementing the knowledge of cardiovascular (CV) risk in patients with rheumatoid arthritis (RA) into clinical practice. Our aim was to evaluate CV risk factor (CVRF) recording in a rheumatology outpatient clinic (ROC), where the standard was annual CVRF recording. A second aim was to compare CVRF recording between a regular ROC (RegROC) and an arthritis clinic (AC), which consisted of a structured, team-based model. <h3>Methods</h3> In 2012, 1142 RA patients visited the ROC of the Hospital of Southern Norway. Of these 612 attended RegROC and 530 attended AC. We conducted a search in the patients9 hospital records to identify recording of CVRFs. <h3>Results</h3> CVRFs were recorded in 38.2% of the patients. All the CVRFs included in the European CV risk calculator, systematic coronary risk evaluation (SCORE) were recorded in only 26.9% of the patients. Overall, the rate of CVRF recording was 50.4% for blood pressure, 47.0% for total cholesterol, 30.7% for fasting blood glucose, 33.7% for HbA1c, 66.2% for smoking, 22% for CV medication and 20.2% for CV co-morbidities. When comparing AC versus RegROC, odds ratios for CVRFs being recorded in the patient journal was for: BP: 12.4, the various lipids: 5.0-6.0, fasting blood glucose: 9.1, HbA1c: 6.1, smoking: 1.4, CV medication: 6.3 and CV co-morbidities: 6.4. <h3>Conclusions</h3> The overall CVRF recordings were low in a ROC, although a systematic team-based model increased CVRF recording significantly; it was still suboptimal compared to what is shown for other high CV risk patients. There is an unmet need for systems improving CVRF recording in RA patients. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4321
Incidental Second Primary in the Breast Detected by F-18 FDG Positron Emission Tomography Scan
Authors: S M Bakheet, J Powe, A Ezzat, Y Bakri
Journal: Clinical Nuclear Medicine (1998)

A 39-year-old women had multiple lung lesions on a follow-up chest radiograph after laparotomy and left cystectomy for an immature ovarian teratoma. Results of a work-up for metastases were normal, including beta human chorionic gonadotrophin and alpha-fetoprotein levels. An F-18 FDG positron emission tomographic (PET) whole-body scan performed to evaluate the possibility of pulmonary metastases showed no abnormality in the chest or pelvis. There was intense focal uptake in the left breast, however, suggesting an incidental second malignancy. Pathologic evaluation of the left breast mass showed infiltrating ductal cell carcinoma, for which she received chemotherapy. Histologic examination of the lung lesions showed a benign mature teratoma in one nodule and fibrosis in several of the others. In a patient with a neoplasm, F-18 FDG uptake on a whole-body scan may be unrelated to the primary tumor and could represent an incidental second malignancy.
Abstract 5280: Activation of sphingosine kinase 1 is necessary for angiopoietin 2-induced hemangiogenesis and lymphangiogenesis
Authors: Akimitsu Yamada, Masayuki Nagahashi, Subramaniam Ramachandran, Eugene Y. Kim, Jeremy C. Allegood, Omar M. Rashid, Sheldon Milstien, Sarah Spiegel, Kazuaki Takabe
Journal: Cancer Research (2012)

Abstract INTRODUCTION: Sphingosine kinase 1 (SphK1) is one of the two isoenzymes that generate the potent bioactive sphingolipid mediator, sphingosine-1-phosphate (S1P). S1P promotes cancer cell survival, proliferation and hemangiogenesis. The angiopoietin2 (Ang2)-Tie2 axis also plays a significant role in hemangiogenesis and lymphangiogenesis. The aim of this study was to investigate the involvement of SphK1 in Ang2-induced hem- and lymphangiogenesis. METHODS: Human umbilical vein endothelial cells (HUVECs) and human lymphatic endothelial cells (HLECs) were treated without or with an isozyme-specific inhibitor of SphK1 (SK1-I) and qPCR, western blot, ELISA, and tube formation assays carried out. We also used a new method we developed to quantify both hem- and lymphangiogenesis in the same sample in vivo by combining Directed In Vivo Angiogenesis Assays (DIVAA) with Fluorescence Activated Cell Sorting (DIVAA/FACS). RESULTS: qPCR revealed that human HLECs like HUVECs express high levels of SphK1 and the S1PR1 receptor. S1P rapidly stimulated xocytosis of Ang2 from HLEC storage granules determined by ELISA. Ang2 activated Tie2 in HLECs as demonstrated by its rapid phosphorylation on Tyr992, a major site responsible for its activation. Similar to Ang2, S1P also stimulated phosphorylation of Tie2, which may be due to secretion of Ang2. S1P is a potent hem- and lymphangiogenic factor for HUVECs and HLECs, respectively, as demonstrated by enhanced tube formation. Ang2-induced hem- and lymphangiogenesis was mediated at least in part by SphK1 as shown by the inhibitory effect of SK1-I. Furthermore, both S1P and Ang2 significantly induced hem- and lymphangiogenesis in vivo determined by DIVAA/FACS. Similar to its effect on in vitro hem- and lymphangiogenesis, inclusion of SK1-I in the angioreactors together with Ang2 completely abolished its ability to stimulate both of these processes. CONCLUSION: Activation of SphK1 is necessary for Ang2-induced hemangiogenesis and lymphangiogenesis through the SphK1/S1P and Ang2/Tie2 axes. This work was supported by NIH (K12HD055881) and Susan G. Komen for the Cure (KG090510) to KT, NCI (R01CA61774) to SS, and Sumitomo Life Social Welfare Services Foundation grant to MN. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5280. doi:1538-7445.AM2012-5280
Recognizing sessile serrated adenomas/polyps: a diagnostic challenge for pathologists
Authors: Runjan Chetty
Journal: Endoscopy (2013)

In the past 15 years, it has become increasingly clear that a significant proportion of colorectal cancers arise from a serrated precursor lesion rather than the conventional adenoma. These lesions are known as sessile serrated adenoma or polyps (SSA/P) and are mediated by a different molecular (serrated) pathway to the chromosomal instability pathway. Several researchers have suggested that the serrated pathway is an accelerated one leading to carcinogenesis. For these reasons, it is imperative that both gastroenterologists and pathologists are not only aware of the existence of SSA/P, but are able to make the correct diagnosis and, subsequently, to manage the patient appropriately.
MALARIA CONTROL IN PALESTINE
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAFETY AND EFFICACY OF PRO ANP 31-67 IN CARDIORENAL SYNDROME: A FIRST-IN-HUMAN TRIAL
Authors: Sinny Delacroix, Ramesh Chokka, Adam Nelson, Samuel Sidharta, Karen Teo, Jonathan Tuke, Richard Upton, Paul E. Rolan, Stephen Worthley
Journal: Journal of the American College of Cardiology (2016)
Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma
Authors: B. Chmielowski
Journal: British Journal of Dermatology (2016)

Journal Article Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma Get access B. Chmielowski B. Chmielowski Division of Hematology – Medical Oncology Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles CA 90049 U.S.A https://orcid.org/0000-0002-2374-3320 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 174, Issue 1, 1 January 2016, Page 20, https://doi.org/10.1111/bjd.14251 Published: 01 January 2016
PTU-038 Prolonged Overt Obscure Gastrointestinal Bleeding – A “real World” Experience
Authors: P Sattianayagam, P Desmond, A Taylor
Journal: Gut (2014)

<h3>Introduction</h3> Prolonged overt obscure gastrointestinal bleeding (OGIB) after an initial normal oesophagogastroduodenoscopy and colonoscopy can be difficult to manage. “Real-world” studies with all of the endoscopic (capsule endoscopy, device-assisted enteroscopy), radiological (radionuclide red cell scan, CT angiography and angiographic embolisation) and surgical interventions or therapies are lacking. <h3>Methods</h3> We studied the investigation and treatment of such patients, requiring transfusion with ≥1 inpatient stay of 7 days between 2004 and 2012 at St. Vincent’s Hospital and Epworth Eastern Hospital, Melbourne, Australia. <h3>Results</h3> Twenty-eight patients presented at a median age of 67.5 years. The median blood transfusion requirement per patient from symptom presentation to diagnosis or census was 26 units. Anti-platelet and anticoagulation therapy was taken by 50% patients. Twenty-four had diagnoses made (21 small and 3 large intestinal). These included angioectasias in 8 patients (6 small and 2 large bowel) who were &gt;65 years and six of whom were taking anti-platelet therapy for cardiac disease; portal hypertensive enteropathy/ small bowel varices in four patients who were &lt;60 years; and small intestinal tumours in 5 patients (2 gastrointestinal stromal tumours and 3 carcinoid tumours), the latter of which needed surgery for diagnosis and treatment in all cases. Repeat gastroscopy allowed histoacryl glue injection of peri-anastomotic varices in one case and repeat colonoscopy permitted treatment of angioectasias in two elderly patients. Radionuclide red cell scans had the highest radiological diagnostic yield (51%) but were beneficial only in conjunction with other tests. CT angiography (diagnostic yield 30%) resulted in successful angiographic embolisation in 3/9 cases (a small intestinal angioectasia and bleeding associated with colonic diverticula and a pancreaticoduodenal artery pseudoaneurysm). Capsule endoscopy had the highest endoscopic diagnostic yield (53%). In two patients repeat examination was diagnostic (an angioectasia and a gastrointestinal stromal tumour). Antegrade double balloon enteroscopy had the best enteroscopic yield (31%). In 2 cases it allowed argon plasma coagulation of small intestinal angioectasias, which were missed by prior enteroscopy. Surgery had a diagnostic and therapeutic yield of 60%. <h3>Conclusion</h3> Prolonged overt OGIB is difficult to manage. There may be clues to the underlying diagnosis from the history and clinical features. Capsule endoscopy is a good first-line test, which can guide enteroscopy. Similarly CT angiography can guide angiographic embolisation. Surgery is best as a last resort but is not always productive. Management should be individualised with consideration given to repeating investigations. <h3>Disclosure of Interest</h3> None Declared.